Stay in touch
Prime news from our network.
#read
Biotechnology financing in Germany increases by 78 per cent
The financing of German biotechnology companies increased by 78 per cent to 1.917 billion euros in 2024. This was mainly due to venture capital (898 million euros), capital increases (999 million euros) and an IPO (20 million euros). This is the result of an analysis by BIO Deutschland and EY.
31/01/2025
Both private (+68 per cent) and public companies (+82 per cent) benefited from this development. Excluding the record sums raised by BioNTech and CureVac due to the pandemic, an all-time high was even reached. At 32, the number of venture capital financing rounds was significantly higher than in previous years (2023: 21). The industry has made an impressive recovery, but the financing conditions remain difficult," says Oliver Schacht, Managing Director of BIO Deutschland. He calls for initiatives such as WIN to be driven forward. Viola Bronsema, Managing Director of BIO Deutschland, emphasises the importance of venture capital for innovation: „Biotechnology offers enormous potential, not only in medicine, but also in nutrition.“ According to EY expert Klaus Ort, biotechnology is a growth market with ground-breaking technologies that can strengthen Germany economically and socially.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.